Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 515

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 515
---
 growth hormones of human, bovine, and porcine, hepatitis B vaccine, interferon alpha and gamma, GM -CSF, EPO, etc. Moreover, four drug candidates were licensed out to multinational pharmaceutical companies under his supervision and one of them is approved by FDA (US). On the basis of such achievements, Dr. Cho has received many awards 323 and acted as a member of governmental committees. He received his Ph.D. from University of Houston and worked as a post -docin Baylor College of Medicine. Dr. Cho is an author of more than 80 publications in books and journals including Nature, and an inventor of more than 200 patents filed. Dr. Cho is well qualified to serve as a director because of long -standingcareer experiences both as a biotech entrepreneur and the R&D Head of a major life sciences company in Korea (LG Group). Family Relationships There are no family relationships among any of the individuals who shall serve as the directors or executive officers of New OSR Holdings following the consummation of the Business Combination. Composition of the New OSR Holdings Board New OSR Holdings business and affairs will be managed under the direction of the New OSR Holdings Board. New OSR Holdings anticipates that the New OSR Holdings Board will consist of nine (9) members upon Closing of the Business Combination. Mr. Kuk Hyoun Hwang will serve as Chief Executive Officer and Chairman of the New OSR Holdings Board. Mr. Phil Geon Lee will serve as the lead independent director of New OSR Holdings. The primary responsibilities of the New OSR Holdings Board will be to provide oversight, strategic guidance, counseling and direction to New OSR Holdings’ management. The New OSR Holdings Board will meet on a regular basis and on an ad hoc basis as required. Subject to applicable law and the Amended Charter and subject to the rights of the holders of any series of New OSR Holdings Preferred Stock, any vacancy on the New OSR Holdings Board shall be filled only by the New OSR Holdings Board and not by the stockholders of New OSR Holdings. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director’s successor shall have been elected and qualified. Director Independence Nasdaq rules generally require that independent directors must comprise a majority of a listed company’s board of directors. Based upon information requested from and provided by each proposed director concerning his or her background, employment and affiliations